P. Taslimi

发表

Kinase chemogenomics: targeting the human kinome for target validation and drug discovery.

G. Bemis, W. P. Walters, F. Salituro, 2004, Mini reviews in medicinal chemistry.

The Structure of Dimeric ROCK I Reveals the Mechanism for Ligand Selectivity*

M. Fleming, L. Swenson, K. Hayakawa, 2006, Journal of Biological Chemistry.

Resveratrol inhibits firefly luciferase.

Adel Bakhtiarova, D. Kemp, B. Hubbard, 2006, Biochemical and biophysical research communications.

Investigation of functionally liver selective glucokinase activators for the treatment of type 2 diabetes.

A. Duttaroy, Jiaping Gao, Valerie Beaulieu, 2009, Journal of medicinal chemistry.

Optimization of Allosteric With-No-Lysine (WNK) Kinase Inhibitors and Efficacy in Rodent Hypertension Models.

Y. Yagi, Mitsunori Kato, Monish Jain, 2017, Journal of medicinal chemistry.

Design , Synthesis , and Structure − Activity Relationships of Pyridine-Based Rho Kinase ( ROCK ) Inhibitors

D. Newsome, P. Taslimi, M. Jacobs, 2015 .

New insights into the structure-function relationships of Rho-associated kinase: a thermodynamic and hydrodynamic study of the dimer-to-monomer transition and its kinetic implications.

T. Fox, P. Taslimi, J. Doran, 2004, The Biochemical journal.

Discovery and SAR of novel 4-thiazolyl-2-phenylaminopyrimidines as potent inhibitors of spleen tyrosine kinase (SYK).

Jian Wang, G. Bemis, F. Salituro, 2008, Bioorganic & medicinal chemistry letters.

Discovery of Mobocertinib, a Potent, Oral Inhibitor of EGFR Exon 20 Insertion Mutations in Non-Small Cell Lung Cancer.

T. Clackson, A. Gould, V. Rivera, 2022, Bioorganic & medicinal chemistry letters.

Protein Complex Interactor Analysis and Differential Activity of KDM3 Subfamily Members Towards H3K9 Methylation

I. Clay, A. Bauer, H. Ruffner, 2013, PloS one.

Staurosporine-based binding assay for testing the affinity of compounds to protein kinases.

S. Pazhanisamy, G. Iyer, P. Taslimi, 2008, Analytical biochemistry.

The Discovery of VX-745: A Novel and Selective p38α Kinase Inhibitor.

Huai Gao, Yow-Ming Wang, Yow-Ming C Wang, 2011, ACS medicinal chemistry letters.

Structure-based design and parallel synthesis of N-benzyl isatin oximes as JNK3 MAP kinase inhibitors.

G. Bemis, F. Salituro, Edmund M. Harrington, 2009, Bioorganic & medicinal chemistry letters.

Abstract 2644: AP32788, a potent, selective inhibitor of EGFR and HER2 oncogenic mutants, including exon 20 insertions, in preclinical models

V. Rivera, T. Zhou, M. Greenfield, 2016 .

Structure-based design and parallel synthesis of N-benzyl isatin oximes as JNK3 MAP kinase inhibitors.

G. Bemis, F. Salituro, Edmund M. Harrington, 2009, Bioorganic & medicinal chemistry letters.

Investigation of functionally liver selective glucokinase activators for the treatment of type 2 diabetes.

A. Duttaroy, Jiaping Gao, Valerie Beaulieu, 2009, Journal of medicinal chemistry.